Lack of reduction of left ventricular mass in treated hypertension: The strong heart study

Journal of the American Heart Association

Volumn 2, Issue 3, 2013, Pages

  De Simone, Giovanni ^a,b   Devereux, Richard B ^b   Izzo, Raffaele ^a   Girfoglio, Daniela ^a   Lee, Elisa T ^c   Howard, Barbara V ^d   Roman Mary J , M J ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF OKLAHOMA   (United States)

^d MEDSTAR RESEARCH INSTITUTE   (United States)

Author keywords

Antihypertensive therapy; Blood pressure; Obesity; Proteinuria; Ventricular hypertrophy

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART RATE; HUMAN; HYPERTENSION; KIDNEY INJURY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBESITY; POPULATION RESEARCH; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; WAIST HIP RATIO; AGED; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; HEART VENTRICLE HYPERTROPHY; MIDDLE AGED; PROTEINURIA; COMPLICATION; HYPERTROPHY, LEFT VENTRICULAR;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; OBESITY; PROTEINURIA; VENTRICULAR HYPERTROPHY;

AGED; ANTIHYPERTENSIVE AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LONGITUDINAL STUDIES; MALE; MIDDLE AGED;

EID: 84883293339     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.113.000144     Document Type: Article

References (44)

1. Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004;110:1456-1462.
2. De Luca N, Mallion JM, O'Rourke MF, O'Brien E, Rahn KH, Trimarco B, Romero R, de Leeuw PW, Hitzenberger G, Battegay E, Duprez D, Sever P, Safar ME. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens. 2004;17:660-667.
3. Gosse P, Sheridan DJ, Zannad F, Dubourg O, Gueret P, Karpov Y, de Leeuw PW, Palma-Gamiz JL, Pessina A, Motz W, Degaute JP, Chastang C. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens. 2000;18:1465- 1475.
4. Dahlof B, Gosse P, Gueret P, Dubourg O, de Simone G, Schmieder R, Karpov Y, Garcia-Puig J, Matos L, de Leeuw PW, Degaute JP, Magometschnigg D. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens. 2005;23:2063-2070.
5. Malmqvist K, Kahan T, Edner M, Held C, Hagg A, Lind L, Muller-Brunotte R, Nystrom F, Ohman KP, Osbakken MD, Ostergern J. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens. 2001;19:1167-1176.
6. Gosse P, Cremer A, Vircoulon M, Coulon P, Jan E, Papaioannou G, Yeim S. Prognostic value of the extent of left ventricular hypertrophy and its evolution in the hypertensive patient. J Hypertens. 2012;30:2403-2409.
7. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlof B. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004;292: 2350-2356.
8. Cuspidi C, Esposito A, Negri F, Sala C, Masaidi M, Giudici V, Zanchetti A, Mancia G. Studies on left ventricular hypertrophy regression in arterial hypertension: a clear message for the clinician? Am J Hypertens. 2008; 21:458-463.
9. Martin K, Begaud B, Latry P, Miremont-Salame G, Fourrier A, Moore N. Differences between clinical trials and postmarketing use. Br J Clin Pharmacol. 2004;57:86-92.
10. Pereira TV, Horwitz RI, Ioannidis JP. Empirical evaluation of very large treatment effects of medical interventions. JAMA. 2012;308:1676-1684.
11. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension. 2009;54:1084-1091.
12. Lee ET, Fabsitz R, Cowan LD, Le NA, Oopik AJ, Cucchiara AJ, Savage PJ, Howard BV. The Strong Heart Study-a study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol. 1990;136: 1141-1155.
13. Drukteinis JS, Roman MJ, Fabsitz RR, Lee ET, Best LG, Russell M, Devereux RB. Cardiac and systemic hemodynamic characteristics of hypertension and prehypertension in adolescents and young adults: the Strong Heart Study. Circulation. 2007;115:221-227.
14. Chinali M, de Simone G, Roman MJ, Best LG, Lee ET, Russell M, Howard BV, Devereux RB. Cardiac markers of pre-clinical disease in adolescents with the metabolic syndrome: the Strong Heart Study. J Am Coll Cardiol. 2008;52:932-938.
15. de Simone G, Devereux RB, Chinali M, Best LG, Lee ET, Galloway JM, Resnick HE. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study. Diabetes Care. 2007;30:1851-1856.
16. Devereux RB, Roman MJ, de Simone G, O'Grady MJ, Paranicas M, Yeh JL, Fabsitz RR, Howard BV. Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: the Strong Heart Study. Circulation. 1997;96:1416-1423.
17. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux RB, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, Silverman NH, Tajik AJ. Recommendations for quantitation of the left ventricle by two- dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358-367.
18. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
19. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, Alderman MH. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992;20:1251-1260.
20. de Simone G, Kizer JR, Chinali M, Roman MJ, Bella JN, Best LG, Lee ET, Devereux RB. Normalization for body size and population-attributable risk of left ventricular hypertrophy The Strong Heart Study. Am J Hypertens. 2005;18:191-196.
21. Jordan J, Yumuk V, Schlaich M, Nilsson PM, Zahorska-Markiewicz B, Grassi G, Schmieder RE, Engeli S, Finer N. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens. 2012;30:1047-1055.
22. Bhan V, Yan RT, Leiter LA, Fitchett DH, Langer A, Lonn E, Tan M, Silagy S, Goodman SG, Yan AT. Relation between obesity and the attainment of optimal blood pressure and lipid targets in high vascular risk outpatients. Am J Cardiol. 2010;106:1270-1276.
23. Arcucci O, de Simone G, Izzo R, Rozza F, Chinali M, Rao MA, Bodenizza C, De Luca N, Trimarco B. Association of suboptimal blood pressure control with body size and metabolic abnormalities. J Hypertens. 2007;25: 2296-2300.
24. Czernichow S, Castetbon K, Salanave B, Vernay M, Barry Y, Batty GD, Hercberg S, Blacher J. Determinants of blood pressure treatment and control in obese people: evidence from the general population. J Hypertens. 2012;30:2338-2344.
25. de Simone G, Okin PM, Gerdts E, Olsen MH, Wachtell K, Hille DA, Dahl€of B, Kjeldsen SE, Devereux RB. Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study. Nutr Metab Cardiovac Dis. 2009;19:634-640.
26. Gerdts E, de Simone G, Lund BP, Okin PM, Wachtell K, Boman K, Nieminen MS, Dahlof B, Devereux RB. Impact of overweight and obesity on cardiac benefit of antihypertensive treatment. Nutr Metab Cardiovasc Dis. 2013;23:122-129.
27. Carpenter HM. Myocardial fat infiltration. Am Heart J. 1962;63:491-496. 28. Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A. Blood-pressure control in the hypertensive population. Lancet. 1997;349:454-457.
28. Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A. Blood-pressure control in the hypertensive population. Lancet. 1997;349:454-457.
29. de Simone G, De Marco M. Sodium, left ventricular mass, and arterial hypertension: is it time to look for a new paradigm. Hypertension. 2011;58: 349-351.
30. de Simone G, Devereux RB, Roman MJ, Schlussel Y, Alderman MH, Laragh JH. Echocardiographic left ventricular mass and electrolyte intake predict arterial hypertension. Ann Intern Med. 1991;114:202-209.
31. Mahoney LT, Schieken RM, Clarke WR, Lauer RM. Left ventricular mass and exercise responses predict future blood pressure. The Muscatine Study. Hypertension. 1988;12:206-213.
32. Post WS, Larson MG, Levy D. Impact of left ventricular structure on the incidence of hypertension. The Framingham Heart Study. Circulation. 1994; 90:179-185.
33. de Simone G, Devereux RB, Chinali M, Roman MJ, Welty TK, Lee ET, Howard BV. Left ventricular mass and incident hypertension in individuals with initial optimal blood pressure: the Strong Heart Study. J Hypertens. 2008;26:1868-1874.
34. Devereux RB. Does increased blood pressure cause left ventricular hypertrophy or vice versa? Ann Intern Med. 1990;112:157-159.
35. Nallamothu BK, Hayward RA, Bates ER. Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation. 2008;118:1294-1303.
36. Sipido KR, Tedgui A, Kristensen SD, Pasterkamp G, Schunkert H, Wehling M, Steg PG, Eisert W, Rademakers F, Casadei B, Fuster V, Cerbai E, Hasenfuss G, Fernandez-Aviles F, Garcia-Dorado D, Vidal M, Hallen M, Dambrauskaite V. Identifying needs and opportunities for advancing translational research in cardiovascular disease. Cardiovasc Res. 2009;83:425-435.
37. de Simone G. Regression of LVH or reduction of left ventricular mass? Am J Hypertens. 2008;21:365-366.
38. Devereux RB, Dahlof B, Levy D, Pfeffer MA. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). Am J Cardiol. 1996;78:61-65.
39. Alpert MA, Kelly DL. Value and limitations of echocardiography in the assessment of obese patients. Echocardiograhy. 1986;3:261-272.
40. Rao SC, Kusnetzky LL, Lan X, Main ML. Temporal obesity trends in patients undergoing transthoracic echocardiography. Am J Cardiol. 2009;103:688-689.
41. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of Obesity in the United States, 2009-2010. Hyattsville, MD: National Center for Health Statistics; 2012. NCHS Data Brief, 82, January 1, 2012.
42. Devereux RB, Roman MJ, Liu JE, Lee ET, Wang W, Fabsitz RR, Welty TK, Howard BV. An appraisal of echocardiography as an epidemiological tool. The Strong Heart Study. Ann Epidemiol. 2003;13:238-244
43. De Luca N, Izzo R, Iaccarino G, Malini PL, Morisco C, Rozza F, Iovino GL, Rao MA, Bodenizza C, Lanni F, Guerrera L, Arcucci O, Trimarco B The use of a telematic connection for the follow-up of hypertensive patients improves the cardiovascular prognosis. J Hypertens. 2005;23:1417-1423.
44. Izzo R, de Simone G, Trimarco V, Giudice R, Mancusi C, Sforza A, Rao MA, De Luca N, Trimarco B. Clinical predictors of development of new LV hypertrophy in treated hypertensive patients (Abstract). Circulation. 2012;126:A14284.